SEC Form 4 · accession 0001349929-16-000064
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Pappajohn
Director · 10% Owner
Period of report
Mar 15, 2016
Accepted (ET)
Mar 16, 2016 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Mar 15, 2016 | P | 89,421 | $2.5178 | A | 1,711,210 | D | |
| Common Stock, par value $0.0001 per shareF2 | Mar 16, 2016 | P | 10,579 | $2.6216 | A | 1,721,789 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F11. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.23 to $2.60, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F22. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.53 to $2.65, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.